A scientific rationale for protective therapy in Parkinson's disease.
The desire to introduce neuroprotective therapy for Parkinson's disease has begun to focus attention on pathogenetic mechanisms responsible for cell death. Considerable theory and some evidence have now accumulated to suggest that factors related to oxidative stress, mitochondrial bioenergetic defects, excitatory neurotoxicity, calcium cytotoxicity, and trophic factor deficiencies acting either singularly or in combination may contribute to the development of cell death in Parkinson's disease. A better understanding of the specific pathogenetic mechanism involved in cell degeneration might provide a scientific basis for testing a putative neuroprotective therapy. This chapter reviews the theory and evidence in support of these different mechanisms and possible strategies that might provide neuroprotection and interfere with the natural progression of Parkinson's disease.
Olanow
C W
CW
Department of Neurology, University of South Florida, Tampa.
D000978:Antiparkinson Agents / Q000145:classification / Q000494:pharmacology / Q000627:therapeutic use*; D002118:Calcium / Q000378:metabolism; D016923:Cell Death; D002986:Clinical Trials as Topic; D004298:Dopamine / Q000378:metabolism; D005609:Free Radicals; D006706:Homeostasis; D006801:Humans; D008928:Mitochondria / Q000502:physiology; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D009414:Nerve Growth Factors / Q000627:therapeutic use; D009498:Neurotoxins / Q000378:metabolism; D010084:Oxidation-Reduction; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology / Q000517:prevention & control; D012642:Selegiline / Q000494:pharmacology / Q000627:therapeutic use
D000978:Antiparkinson Agents; D005609:Free Radicals; D008996:Monoamine Oxidase Inhibitors; D009414:Nerve Growth Factors; D009498:Neurotoxins; D012642:Selegiline; D002118:Calcium; D004298:Dopamine